Giatromanolaki et al. [20] found that CYP17A1 was overexpressed in the cytoplasm of PCa cells and was directly related to AR expression in cancer cell nuclei and that the application of abiraterone, in addition to inhibiting CYP17A1 expression, could also block the secretion of AR and thus block the nuclear accumulation of AR. The gene discussed is CYP17A1; the disease is posterior cortical atrophy.